Assessment of proton pump inhibitors utilization in intensivecare units patients of a tertiary care hospital in the United ArabEmirates
Main Article Content
Keywords
Proton pump inhibitors, intensive care unit, stress ulcer prophylaxis, utilization, safety
Abstract
Background: PPI prescriptions have consistently increased in hospitals and ambulatory care facilities. Because PPIs are widely used, readily available, highly effective, and heavily marketed, they are susceptible to over-prescription and misuse. This study aims to assess the PPI utilization pattern and prescribing appropriateness in terms of indication, dose, and route of administration in the ICU setting. Methods: A retrospective, cohort study performed from October 2020 - October 2022 in a tertiary care hospital in the UAE. All patients received a proton pump inhibitor in the ICU. Results: Only 20.3% had an appropriate indication for prophylaxis and matched either of the 1 major criteria of SUP or at least 2 minor criteria. The highest percentage of patients (66.2%) were receiving inappropriate prophylaxis therapy. Pantoprazole was the most commonly prescribed PPI followed by Esomeprazole and Lansoprazole. PPI dose was appropriate in 66.9% of the patients and PPI route of administration was appropriate in 87.8% of the patients. Total PPI appropriateness was achieved in only 17.6% of the patients. Patients with moderate GI bleeding risk and who are non-smokers are more likely to have total PPI inappropriateness. Conclusion: This study identified a significant number of inappropriate prescriptions of PPIs for critically ill patients, not in accordance with clinical guidelines. These findings underscore the necessity for educational interventions aimed at physicians to promote more rational prescribing practices.
References
2. Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci.2019;20:5203. https://doi.org/10.3390/ijms20205203
3. Liu Y, Zhu X, Li R, et al. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open. 2020;10:e040473. https://doi.org/10.1136/bmjopen-2020-040473
4. Katz MH. Failing the acid test: Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170:747-748. https://doi.org/10.1001/archinternmed.2010.64
5. Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:1756284818777943. https://doi.org/10.1177/1756284818777943
6. Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Medica. 2018;109: 386-399. https://doi.org/10.23736/s0026-4806.18.05705-1
7. O’Mahony L, Yelverton E. Prescribing of proton pump inhibitors in an Irish general practice. Ir Med J. 2019;112:932.
8. Madi L, Ahmed Elhada AH, Alrawashdeh H, Ahmed A. Prescribing pattern of proton pump inhibitors in Qatar rehabilitation institute: A retrospective study. J Res Pharm Pract. 2019; 8: 101-104. https://doi.org/10.4103/jrpp.jrpp_18_79
9. Jarbøl DE, Lykkegaard J, Hansen JM, et al. Prescribing of proton-pump inhibitors: Auditing the management and reasons for prescribing in Danish general practice. Fam Pract. 2019;36:758-764. https://doi.org/10.1093/fampra/cmz025
10. Kazberuk M, Brzósko S, Hryszko T, et al. Overuse of proton pump inhibitors and its consequences. Postepy Hig Med Dosw (Online). 2016;70:1112-1116. https://doi.org/10.5604/17322693.1222106
11. Hammond DA, Killingsworth CA, Painter JT, et al. Impact of targeted educational interventions on appropriateness of stress ulcer prophylaxis in critically ill adults. Pharm Pract (Granada). 2017;15(3):948. https://doi.org/10.18549/PharmPract.2017.03.948
12. Masood U, Sharma A, Bhatti Z, et al. A Successful Pharmacist-Based Quality Initiative to Reduce Inappropriate Stress Ulcer Prophylaxis Use in an Academic Medical Intensive Care Unit. Inquiry. 2018;55:46958018759116. https://doi.org/10.1177/0046958018759116
13. Lin PC, Chang CH, Hsu PI, et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197-1205. https://doi.org/10.1097/CCM.0b013e3181d69ccf
14. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64(13):1396-1400. https://doi.org/10.2146/ajhp060393
15. Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693-705. https://doi. org/10.1097/CCM.0b013e3182758734
16. Damji SS, Rabbani SA, Rao PGM, et al. Proton pump inhibitor use and appropriateness analysis: a snapshot from a secondary care hospital. Journal of Pharmaceutical Health Services Research. 2021;12(2):206–212. https://doi.org/10.1093/jphsr/rmab013
17. Quenot JP, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15(2):139-43. PMID: 19578324, https://doi.org/10.1097/MCC.0b013e32832978e0
18. Tielleman T, Bujanda D, Cryer B. Epidemiology and Risk Factors for Upper Gastrointestinal Bleeding. Gastrointest Endosc Clin N Am. 2015;25(3):415-28. PMID: 26142028. https://doi.org/10.1016/j.giec.2015.02.010
19. Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci. 2009;54: 1947-1952. https://doi.org/10.1007/s10620-008-0568-4
20. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003;139:843-857. https://doi.org/10.7326/0003-4819-139-10-200311180-00012
21. Akram F, Huang Y, Lim V, et al. Proton pump inhibitors: Are we still prescribing them without valid indications? Australas Med J. 2014;7(11):465-70. PMID: 25550719; PMCID: PMC4259212. https://doi.org/10.4066/AMJ.2014.2093
22. Madi L, Ahmed Elhada AH, Alrawashdeh H, et al. Prescribing Pattern of Proton Pump Inhibitors in Qatar Rehabilitation Institute: A Retrospective Study. J Res Pharm Pract. 2019;8(2):101-104. PMID: 31367645, PMCID: PMC6636417, https://doi. org/10.4103/jrpp.JRPP_18_79
23. Spiegel BM, Dulai GS, Lim BS, et al. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol. 2006;4(8):988-997. https://doi.org/10.1016/j.cgh.2006.05.019
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.